Graft-versus-host disease
SNDXSyndax PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Axatilimab (SNDX-6352) + Steroids in Graft-versus-host disease . The expected timing is based on the latest available company guidance and may change.
Collab w/ Incyte, initiate Ph3 comb trial in mid-2024. 11/03/25:- Pivotal Ph3 Niktimvo+steroids trial in newly diagnosed chronic GVHD patients ≥12 years remains ongoing. 02/26/26:- Pivotal Ph3 Niktimvo+steroids chronic GVHD trial NCT06585774 reiterated as ongoing. 04/30/26:- Ph3 Niktimvo+steroids topline chronic GVHD data anticipated in early 2028. 08/04/26:- Ph3 axatilimab plus corticosteroids topline data reiterated for Early 2028.
Verification
Confirm timing and program details against the company announcement or filing.